Sunmax Biotechnology Co Ltd (TWO:4728) — Market Cap & Net Worth
Market Cap & Net Worth: Sunmax Biotechnology Co Ltd (4728)
Sunmax Biotechnology Co Ltd (TWO:4728) has a market capitalization of $664.90 Million (NT$21.10 Billion) as of May 4, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11088 globally and #372 in its home market, demonstrating a -1.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sunmax Biotechnology Co Ltd's stock price NT$387.50 by its total outstanding shares 54463000 (54.46 Million). Analyse cash flow conversion of Sunmax Biotechnology Co Ltd to see how efficiently the company converts income to cash.
Sunmax Biotechnology Co Ltd Market Cap History: 2015 to 2026
Sunmax Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $46.10 Million to $664.90 Million (30.43% CAGR).
Sunmax Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sunmax Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.51x
Sunmax Biotechnology Co Ltd's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.71x
Sunmax Biotechnology Co Ltd's market cap is 0.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $46.10 Million | $111.65 Million | -$44.16 Million | 0.41x | N/A |
| 2016 | $60.33 Million | $155.53 Million | $1.74 Million | 0.39x | 34.59x |
| 2017 | $39.67 Million | $190.13 Million | $16.54 Million | 0.21x | 2.40x |
| 2018 | $68.43 Million | $304.07 Million | $74.66 Million | 0.23x | 0.92x |
| 2019 | $117.39 Million | $594.14 Million | $100.45 Million | 0.20x | 1.17x |
| 2020 | $120.38 Million | $855.85 Million | $238.08 Million | 0.14x | 0.51x |
| 2021 | $126.59 Million | $1.04 Billion | $245.64 Million | 0.12x | 0.52x |
| 2022 | $215.94 Million | $1.40 Billion | $533.83 Million | 0.15x | 0.40x |
| 2023 | $337.44 Million | $1.69 Billion | $625.71 Million | 0.20x | 0.54x |
| 2024 | $480.45 Million | $949.18 Million | $679.40 Million | 0.51x | 0.71x |
Competitor Companies of 4728 by Market Capitalization
Companies near Sunmax Biotechnology Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Sunmax Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sunmax Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Sunmax Biotechnology Co Ltd's market cap moved from $46.10 Million to $ 664.90 Million, with a yearly change of 30.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$664.90 Million | -2.15% |
| 2025 | NT$679.49 Million | +41.43% |
| 2024 | NT$480.45 Million | +42.38% |
| 2023 | NT$337.44 Million | +56.26% |
| 2022 | NT$215.94 Million | +70.58% |
| 2021 | NT$126.59 Million | +5.15% |
| 2020 | NT$120.38 Million | +2.55% |
| 2019 | NT$117.39 Million | +71.53% |
| 2018 | NT$68.43 Million | +72.51% |
| 2017 | NT$39.67 Million | -34.24% |
| 2016 | NT$60.33 Million | +30.85% |
| 2015 | NT$46.10 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Sunmax Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $664.90 Million USD |
| MoneyControl | $664.90 Million USD |
| MarketWatch | $664.90 Million USD |
| marketcap.company | $664.90 Million USD |
| Reuters | $664.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.